Reduction In Lipoprotein (A) With Evolocumab: Elucidation Of The Role Of The Ldl Receptor From Clinical Trials And In-Vitro Models

Frederick Raal,Robert P. Giugliano,Marc S. Sabatine,Michael Koren,Dirk Blom,Nabil G. Seidah,Narimon Honarpour,Armando Lira Pineda,Allen Xue,Simon Jackson,Mei Di,Matthew Peach,Ransi Somaratne,Scott M. Wasserman,Rob Scott,Evan Stein

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2016）

引用 1|浏览17

暂无评分

摘要

Lp(a) is an independent risk factor for cardiovascular disease risk. Statins increase low-density lipoprotein receptor (LDLR) activity but have little effect on Lp(a), while the PCSK9-inhibitor evolocumab consistently reduces Lp(a) 20-30% by a yet unknown mechanism. We investigated the possible role

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要